Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Abstract Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes include...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Keith W. Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. DiNardo, Jan Novak, Vlatko Pejsa, Don Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H. Wei, Cat N. Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2022-04-01
Cyfres:Blood Cancer Journal
Mynediad Ar-lein:https://doi.org/10.1038/s41408-022-00668-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg